Cosentyx (secukinumab) is a biologic drug that is used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the drug patent watch website [1], Cosentyx is a human monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a cytokine involved in the inflammation and immune response.

A study published in the Journal of Dermatological Treatment [2] evaluated the effectiveness of Cosentyx in treating psoriasis and found that the drug was effective in reducing the severity of the disease in a majority of patients. The study did not mention any dosage changes during the treatment period.

According to the prescribing information [3] provided by Novartis, the recommended dosage of Cosentyx for psoriasis is 300 mg administered by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For psoriatic arthritis and ankylosing spondylitis, the recommended dosage is 150 mg or 300 mg administered by subcutaneous injection every 4 weeks.

The prescribing information [3] also states that dose adjustment is not necessary based on age, gender, race, or renal impairment. However, it is recommended to monitor patients for signs of infection and to interrupt or discontinue Cosentyx treatment if a serious infection develops.

In summary, there is no evidence from the sources provided to suggest that the effectiveness of Cosentyx can be improved with dosage changes. The recommended dosage for Cosentyx varies depending on the condition being treated and does not require dose adjustment based on age, gender, race, or renal impairment. It is important to monitor patients for signs of infection and to interrupt or discontinue treatment if a serious infection develops.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422944/
[3] https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf